Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Yang, Heng ^a,b,c,d,e,f   Ma, Yuting ^a,b,c,d,e,f   Chen, Guo ^a,b,c,d   Zhou, Heng ^a,b,c,d,g   Yamazaki, Takahiro ^a,d,h   Klein, Christophe ⁱ   Pietrocola, Federico ^a,b,c,d   Vacchelli, Erika ^a,b,c,d   Souquere, Sylvie ^j   Sauvat, Allan ^a,b,c,d   Zitvogel, Laurence ^a,d,g,h   Kepp, Oliver ^a,b,c,d   Kroemer, Guido ^a,b,c,d,k,l  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e SUZHOU INSTITUTE OF SYSTEMS MEDICINE   (China)

^f PEKING UNION MEDICAL COLLEGE   (China)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h GRCC   (France)

ⁱ CENTRE DE RECHERCHE DES CORDELIERS   (France)

^j Institut Gustave Roussy   (France)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

ATP; chemotherapy; cytotoxic T cells; dendritic cells; HMGB1; Necroptosis; Tumor immunogenicity

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 3; HIGH MOBILITY GROUP B1 PROTEIN; MITOXANTRONE; MIXED LINEAGE KINASE DOMAIN LIKE PROTEIN; OXALIPLATIN; PROTEIN KINASE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CELL DEATH; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; MOUSE; NECROPTOSIS; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR IMMUNITY;

EID: 84965131629     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1149673     Document Type: Article

References (64)

1. M.D.Vesely, M.H.Kershaw, R.D.Schreiber, M.J.Smyth. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; 10.1146/annurev-immunol-031210-101324
2. P.Sharma, J.P.Allison. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015; 161:205-14; PMID:25860605; 10.1016/j.cell.2015.03.030
3. L.Galluzzi, E.Vacchelli, J.M.Bravo-San Pedro, A.Buque, L.Senovilla, E.E.Baracco, N.Bloy, F.Castoldi, J.P.Abastado, P.Agostinis et al. Classification of current anticancer immunotherapies. Oncotarget 2014; 5:12472-508; PMID:25537519; 10.18632/oncotarget.2998
4. L.Zitvogel, L.Galluzzi, M.J.Smyth, G.Kroemer. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; 10.1016/j.immuni.2013.06.014
5. C.Denkert, S.Loibl, A.Noske, M.Roller, B.M.Muller, M.Komor, J.Budczies, S.Darb-Esfahani, R.Kronenwett, C.Hanusch et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-13; PMID:19917869; 10.1200/JCO.2009.23.7370
6. G.Bindea, B.Mlecnik, M.Tosolini, A.Kirilovsky, M.Waldner, A.C.Obenauf, H.Angell, T.Fredriksen, L.Lafontaine, A.Berger et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-95; PMID: 24138885; 10.1016/j.immuni.2013.10.003
7. J.Galon, H.K.Angell, D.Bedognetti, F.M.Marincola. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11-26; PMID:23890060; 10.1016/j.immuni.2013.07.008
8. L.Senovilla, I.Vitale, I.Martins, M.Tailler, C.Pailleret, M.Michaud, L.Galluzzi, S.Adjemian, O.Kepp, M.Niso-Santano et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; 10.1126/science.1224922
9. L.Apetoh, F.Ghiringhelli, A.Tesniere, M.Obeid, C.Ortiz, A.Criollo, G.Mignot, M.C.Maiuri, E.Ullrich, P.Saulnier et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID: 17704786; 10.1038/nm1622
10. A.Tesniere, F.Schlemmer, V.Boige, O.Kepp, I.Martins, F.Ghiringhelli, L.Aymeric, M.Michaud, L.Apetoh, L.Barault et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29:482-91; PMID:19881547; 10.1038/onc.2009.356
11. E.Vacchelli, Y.Ma, E.Baracco, A.Sistigu, D.Enot, F.Pietrocola, H.Yang, S.Adjemian, K.Chaba, M.Semeraro et al. Chemotherapy-induced anti-tumor immunity requires formyl peptide receptor 1. Science 2015; 350:972-8; PMID:26516201; 10.1126/science.aad0779
12. N.Casares, M.O.Pequignot, A.Tesniere, F.Ghiringhelli, S.Roux, N.Chaput, E.Schmitt, A.Hamai, S.Hervas-Stubbs, M.Obeid et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-701; PMID:16365148; 10.1084/jem.20050915
13. M.Obeid, A.Tesniere, F.Ghiringhelli, G.M.Fimia, L.Apetoh, J.L.Perfettini, M.Castedo, G.Mignot, T.Panaretakis, N.Casares et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; 10.1038/nm1523
14. S.Shalapour, J.Font-Burgada, G.Di Caro, Z.Zhong, E.Sanchez-Lopez, D.Dhar, G.Willimsky, M.Ammirante, A.Strasner, D.E.Hansel et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 2015; 521:94-8; PMID:25924065; 10.1038/nature14395
15. T.Panaretakis, O.Kepp, U.Brockmeier, A.Tesniere, A.C.Bjorklund, D.C.Chapman, M.Durchschlag, N.Joza, G.Pierron, P.van Endert et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28:578-90; PMID:19165151; 10.1038/emboj.2009.1
16. Y.Ma, S.Adjemian, S.R.Mattarollo, T.Yamazaki, L.Aymeric, H.Yang, J.P.Portela Catani, D.Hannani, H.Duret, K.Steegh et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729-41; PMID:23562161; 10.1016/j.immuni.2013.03.003
17. I.Martins, Y.Wang, M.Michaud, Y.Ma, A.Q.Sukkurwala, S.Shen, O.Kepp, D.Métivier, L.Galluzzi, J.L.Perfettini et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 2014; 21:79-91; PMID:23852373; 10.1038/cdd.2013.75
18. G.Kroemer, L.Galluzzi, O.Kepp, L.Zitvogel. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; 10.1146/annurev-immunol-032712-100008
19. A.Degterev, Z.Huang, M.Boyce, Y.Li, P.Jagtap, N.Mizushima, G.D.Cuny, T.J.Mitchison, M.A.Moskowitz, J.Yuan. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1:112-9; PMID:16408008; 10.1038/nchembio711
20. S.He, L.Wang, L.Miao, T.Wang, F.Du, L.Zhao, X.Wang Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009; 137:1100-11; PMID:19524512; 10.1016/j.cell.2009.05.021
21. H.Tang, S.Sebti, R.Titone, Y.Zhou, C.Isidoro, T.S.Ross, H.Hibshoosh, G.Xiao, M.Packer, Y.Xie et al. Decreased mRNA expression in human breast cancer is associated with estrogen receptor-negative subtypes and poor prognosis. EBioMedicine 2015; 2:255-63; PMID:25825707; 10.1016/j.ebiom.2015.01.008
22. D.W.Zhang, J.Shao, J.Lin, N.Zhang, B.J.Lu, S.C.Lin, M.Q.Dong, J.Han. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325:332-6; PMID:19498109; 10.1126/science.1172308
23. L.Sun, H.Wang, Z.Wang, S.He, S.Chen, D.Liao, L.Wang, J.Yan, W.Liu, X.Lei et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148:213-27; PMID:22265413; 10.1016/j.cell.2011.11.031
24. H.Wang, L.Sun, L.Su, J.Rizo, L.Liu, L.F.Wang, F.S.Wang, X.Wang Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell 2014; 54:133-46; PMID:24703947; 10.1016/j.molcel.2014.03.003
25. X.Chen, W.Li, J.Ren, D.Huang, W.T.He, Y.Song, C.Yang, W.Li, X.Zheng, P.Chen et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res 2014; 24:105-21; PMID:24366341; 10.1038/cr.2013.171
26. W.J.Kaiser, J.W.Upton, A.B.Long, D.Livingston-Rosanoff, L.P.Daley-Bauer, R.Hakem, T.Caspary, E.S.Mocarski. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 2011; 471:368-72; PMID:21368762; 10.1038/nature09857
27. J.Wu, Z.Huang, J.Ren, Z.Zhang, P.He, Y.Li, J.Ma, W.Chen, Y.Zhang, X.Zhou et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res 2013; 23:994-1006; PMID:23835476; 10.1038/cr.2013.91
28. J.M.Murphy, P.E.Czabotar, J.M.Hildebrand, I.S.Lucet, J.G.Zhang, S.Alvarez-Diaz, R.Lewis, N.Lalaoui, D.Metcalf, A.I.Webb et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 2013; 39:443-53; PMID:24012422; 10.1016/j.immuni.2013.06.018
29. Z.Cai, S.Jitkaew, J.Zhao, H.C.Chiang, S.Choksi, J.Liu, Y.Ward, L.G.Wu, Z.G.Liu. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol 2014; 16:55-65; PMID:24316671; 10.1038/ncb2883
30. A.Kaczmarek, P.Vandenabeele, D.V.Krysko. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 2013; 38:209-23; PMID:23438821; 10.1016/j.immuni.2013.02.003
31. D.V.Krysko, A.D.Garg, A.Kaczmarek, O.Krysko, P.Agostinis, P.Vandenabeele. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; 10.1038/nrc3380
32. F.Ghiringhelli, L.Apetoh, A.Tesniere, L.Aymeric, Y.Ma, C.Ortiz, K.Vermaelen, T.Panaretakis, G.Mignot, E.Ullrich et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; 10.1038/nm.2028
33. F.Aranda, N.Bloy, J.Pesquet, B.Petit, K.Chaba, A.Sauvat, O.Kepp, N.Khadra, D.Enot, C.Pfirschke et al. Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. Oncogene 2015; 34:3053-62; PMID:25065595; 10.1038/onc.2014.234
34. Y.S.Cho, S.Challa, D.Moquin, R.Genga, T.D.Ray, M.Guildford, F.K.Chan. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137:1112-23; PMID:19524513; 10.1016/j.cell.2009.05.037
35. J.Li, T.McQuade, A.B.Siemer, J.Napetschnig, K.Moriwaki, Y.S.Hsiao, E.Damko, D.Moquin, T.Walz, A.McDermott et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 2012; 150:339-50; PMID:22817896; 10.1016/j.cell.2012.06.019
36. M.Michaud, I.Martins, A.Q.Sukkurwala, S.Adjemian, Y.Ma, P.Pellegatti, S.Shen, O.Kepp, M.Scoazec, G.Mignot et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; 10.1126/science.1208347
37. A.Sistigu, T.Yamazaki, E.Vacchelli, K.Chaba, D.P.Enot, J.Adam, I.Vitale, A.Goubar, E.E.Baracco, C.Remédios et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20:1301-9; PMID:25344738; 10.1038/nm.3708
38. T.Yamazaki, D.Hannani, V.Poirier-Colame, S.Ladoire, C.Locher, A.Sistigu, N.Prada, S.Adjemian, J.P.Catani, M.Freudenberg et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 2014; 21:69-78; PMID:23811849; 10.1038/cdd.2013.72
39. V.Toshchakov, B.W.Jones, P.Y.Perera, K.Thomas, M.J.Cody, S.Zhang, B.R.Williams, J.Major, T.A.Hamilton, M.J.Fenton et al. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol 2002; 3:392-8; PMID:11896392; 10.1038/ni774
40. D.Weng, R.Marty-Roix, S.Ganesan, M.K.Proulx, G.I.Vladimer, W.J.Kaiser, E.S.Mocarski, K.Pouliot, F.K.Chan, M.A.Kelliher et al. Caspase-8 and RIP kinases regulate bacteria-induced innate immune responses and cell death. Proc Natl Acad Sci U S A 2014; 111:7391-6; PMID:24799678; 10.1073/pnas.1403477111
41. N.Yatim, H.Jusforgues-Saklani, S.Orozco, O.Schulz, S.R.Barreira daSilva R, C.Reis e Sousa, D.R.Green, A.Oberst, M.L.Albert. RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells. Science 2015; 350:328-34; PMID:26405229; 10.1126/science.aad0395
42. S.Janssens, A.Tinel, S.Lippens, J.Tschopp. PIDD mediates NF-kappaB activation in response to DNA damage. Cell 2005; 123:1079-92; PMID:16360037; 10.1016/j.cell.2005.09.036
43. Y.Yang, F.Xia, N.Hermance, A.Mabb, S.Simonson, S.Morrissey, P.Gandhi, M.Munson, S.Miyamoto, M.A.Kelliher. A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol Cell Biol 2011; 31:2774-86; PMID:21606198; 10.1128/MCB.01139-10
44. L.Zitvogel, A.Tesniere, G.Kroemer. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; PMID:16977338; 10.1038/nri1936
45. H.Matsushita, M.D.Vesely, D.C.Koboldt, C.G.Rickert, R.Uppaluri, V.J.Magrini, C.D.Arthur, J.M.White, Y.S.Chen, L.K.Shea et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482:400-4; PMID:22318521; 10.1038/nature10755
46. A.D.Garg, S.Elsen, D.V.Krysko, P.Vandenabeele, P.de Witte, P.Agostinis. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget 2015; 6:26841-60; PMID:26314964; 10.18632/oncotarget.4754
47. R.Q.Peng, Y.B.Chen, Y.Ding, R.Zhang, X.Zhang, X.J.Yu, Z.W.Zhou, Y.X.Zeng, X.S.Zhang. Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterol 2010; 16:2428-34; PMID:20480531; 10.3748/wjg.v16.i19.2428
48. S.Ladoire, P.-L.Frederique, L.Senovilla, C.Dalban, D.Enot, C.Locher, N.Prada, V.Poirier-Colame, K.Chaba, L.Arnould et al. Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy 2015; 11:1878-90; PMID:26506894; 10.1080/15548627.2015.1082022
49. M.Yang, H.Zhao, L.Guo, Q.Zhang, L.Zhao, S.Bai, M.Zhang, S.Xu, F.Wang, X.Wang et al. Autophagy-based survival prognosis in human colorectal carcinoma. Oncotarget 2015; 6:7084-103; PMID:25762626; 10.18632/oncotarget.3054
50. G.B.Koo, M.J.Morgan, D.G.Lee, W.J.Kim, J.H.Yoon, J.S.Koo, S.I.Kim, S.J.Kim, M.K.Son, S.S.Hong et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res 2015; 25:707-25; PMID:25952668; 10.1038/cr.2015.56
51. A.D.Garg, D.V.Krysko, T.Verfaillie, A.Kaczmarek, G.B.Ferreira, T.Marysael, N.Rubio, M.Firczuk, C.Mathieu, A.J.Roebroek et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31:1062-79; PMID:22252128; 10.1038/emboj.2011.497
52. J.M.Tarr, P.J.Young, R.Morse, D.J.Shaw, R.Haigh, P.G.Petrov, S.J.Johnson, P.G.Winyard, P.Eggleton. A mechanism of release of calreticulin from cells during apoptosis. J Mol Biol 2010; 401:799-812; PMID:20624402; 10.1016/j.jmb.2010.06.064
53. C.Ferraro-Peyret, L.Quemeneur, M.Flacher, J.P.Revillard, L.Genestier. Caspase-independent phosphatidylserine exposure during apoptosis of primary T lymphocytes. J Immunol 2002; 169:4805-10; PMID:12391190; 10.4049/jimmunol.169.9.4805
54. N.Werthmoller, B.Frey, R.Wunderlich, R.Fietkau, U.S.Gaipl. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. Cell Death Dis 2015; 6:e1761; PMID:25973681; 10.1038/cddis.2015.129
55. Z.Huang, S.Q.Wu, Y.Liang, X.Zhou, W.Chen, L.Li, J.Wu, Q.Zhuang, C.Chen, J.Li et al. RIP1/RIP3 binding to HSV-1 ICP6 initiates necroptosis to restrict virus propagation in mice. Cell Host Microbe 2015; 17:229-42; PMID:25674982; 10.1016/j.chom.2015.01.002
56. J.W.Upton, W.J.Kaiser, E.S.Mocarski. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 2012; 11:290-7; PMID:22423968; 10.1016/j.chom.2012.01.016
57. H.Guo, S.Omoto, P.A.Harris, J.N.Finger, J.Bertin, P.J.Gough, W.J.Kaiser, E.S.Mocarski. Herpes simplex virus suppresses necroptosis in human cells. Cell Host Microbe 2015; 17:243-51; PMID:25674983; 10.1016/j.chom.2015.01.003
58. S.Omoto, H.Guo, G.R.Talekar, L.Roback, W.J.Kaiser, E.S.Mocarski. Suppression of RIP3-dependent necroptosis by human cytomegalovirus. J Biol Chem 2015; 290:11635-48; PMID:25778401; 10.1074/jbc.M115.646042
59. L.Galluzzi, O.Kepp, E.Morselli, I.Vitale, L.Senovilla, M.Pinti, L.Zitvogel, G.Kroemer. Viral strategies for the evasion of immunogenic cell death. J Intern Med 2010; 267:526-42; PMID:20433579; 10.1111/j.1365-2796.2010.02223.x
60. O.Kepp, L.Senovilla, L.Galluzzi, T.Panaretakis, A.Tesniere, F.Schlemmer, F.Madeo, L.Zitvogel, G.Kroemer. Viral subversion of immunogenic cell death. Cell Cycle 2009; 8:860-9; PMID:19221507; 10.4161/cc.8.6.7939
61. B.Levine, N.Mizushima, H.W.Virgin. Autophagy in immunity and inflammation. Nature 2011; 469:323-35; PMID:21248839; 10.1038/nature09782
62. F.McNab, K.Mayer-Barber, A.Sher, A.Wack, A.O'Garra. Type I interferons in infectious disease. Nat Rev Immunol 2015; 15:87-103; PMID:25614319; 10.1038/nri3787
63. L.Zitvogel, L.Galluzzi, O.Kepp, M.J.Smyth, G.Kroemer. Type I interferons in anticancer immunity. Nat Rev Immunol 2015; 15:405-14; PMID:26027717; 10.1038/nri3845
64. L.Cong, F.A.Ran, D.Cox, S.Lin, R.Barretto, N.Habib, P.D.Hsu, X.Wu, W.Jiang, L.A.Marraffini et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339:819-23; PMID:23287718; 10.1126/science.1231143